Liposomal formulations of cytotoxic drugs
- 1 July 1996
- journal article
- review article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 4 (4), 298-304
- https://doi.org/10.1007/bf01358884
Abstract
Liposomes are microscopic particles of lipid bilayer membrane that enclose aqueous internal compartments. These drug-delivery systems offer a very interesting opportunity for delivering cytotoxic drugs with equal or improved clinical efficacy and reduced toxicity. The most important clinical application of liposomes until now has been the inclusion of amphotericin B. At the same dose level, liposomal amphotericin B is as effective or slightly less effectivc than the conventional formulation, but much higher dosages, up to 5–7 mg kg−1day−1, can be given with acceptable toxicity. There are three preparations of cytotoxic drugs in an advanced stage of commercial development. Two of these (Doxil and TLD D99) contain doxorubicin and the other (DaunoXome) contains daunorubicin. The cardiac toxicity of the three preparations under clinical evaluation appears to be low in comparison with conventional doxorubicin or daunorubicin. No direct comparisons between the new formulations are available, so it is not yet possible to make any statements concerning their relative efficacy and toxicity. DaunoXome is the only drug that is approved in any country, and is also the best documented. It is too early to make recommendations concerning the place of these drugs in therapy. The marked increase in concentrations at the site of the tumour has yet to lead to increased therapeutic efficacy. These findings need further investigation. The efficacy of liposomal preparations in Kaposi's sarcoma appears to be similar to that of standard therapy and the clinical tolerance is good. Perhaps combination therapy with other cytotoxic agents could result in improved clinical efficacy. Their cost will probably be high in comparison with standard therapies.Keywords
This publication has 30 references indexed in Scilit:
- Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogsAnti-Cancer Drugs, 1994
- Tamoxifen decreases drug efflux from liposomes: Relevance to its ability to reverse multidrug resistance in cancer cells?FEBS Letters, 1994
- Liposomal doxorubicin (Doxil): An effective new treatment for Kaposi's sarcoma in AIDSClinical Oncology, 1994
- Daunoxome® Treatment of Solid Tumors: Preclinical and Clinical InvestigationsJournal of Liposome Research, 1994
- Liposomal doxorubicin for treatment of AIDS-related Kaposi's sarcomaClinical Oncology, 1993
- Liposomes as Carriers of Cancer ChemotherapyDrugs, 1993
- Hepatic toxicity of liposomal encapsulated doxorubicinThe Lancet, 1993
- Fatal hepatic failure with liposomal doxorubicinThe Lancet, 1993
- Liposomal and Lipid Formulations of Amphotericin BClinical Pharmacokinetics, 1992
- Liposomes in haematologyBlood Reviews, 1991